504
Participants
Start Date
October 9, 2023
Primary Completion Date
October 30, 2029
Study Completion Date
October 30, 2031
Cisplatin-based induction chemotherapy
Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy including GP, TP, and TPF regimen.
Full course of PD-1/PD-L1 blockades
a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.
Reduced-dose IMRT
GTVnx:60Gy/30F/2.0Gy，CTV1:54Gy/30F/1.8Gy，CTV2:48Gy/30F/1.6Gy
Standard-dose IMRT
GTVnx：69.96Gy/33Fr/2.12Gy；CTV1：60.60Gy/33Fr/1.82y；CTV2：54.12Gy/33Fr/1.64Gy
Concurrent Chemotherapy
Cisplatin 100mg/m2 every 3 weeks for 2 cycles
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
First Affiliated Hospital, Sun Yat-Sen University
OTHER
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
OTHER
Guangdong Provincial People's Hospital
OTHER
Second Affiliated Hospital, Sun Yat-Sen University
OTHER
The fifth Affiliated Hospital of Guangzhou Medcial University
OTHER_GOV
Zhongshan People's Hospital, Guangdong, China
OTHER
Hunan Cancer Hospital
OTHER
Tongji Hospital
OTHER
Sun Yat-sen University
OTHER